SHL (SHL) Fair Value & Analysis
Healthcare · Market cap A$9.6B
Fair value as of: Jun 25, 2026
From 24 valuation models · updated 7 days ago
Fair value updated Jun 25, 2026 — revised from A$49.45 to A$22.86 (−53.8%) since Jun 24, 2026. Share price +11.8% over the past month.
Price vs Fair Value (12 months)
12‑month range A$17.43 – A$26.19 · fair‑value band A$17.15 – A$28.58 · the A$19.83 price screens below the A$22.86 fair value. As of Jun 25, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
SHL (SHL) currently trades at A$19.83, while our model-based Fair Value estimate is A$22.86 — implying the stock looks roughly 15.3% undervalued today. We read business quality at 57/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
Over the trailing twelve months, SHL generated revenue of A$10.4B at a net margin of 5.2%. Revenue grew 16.6% year over year. It earns a return on equity of 6.6%. Net debt stands at A$4.5B. Fundamentals as of Jun 25, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 25, 2026. TTM = trailing twelve months.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
SHL reported revenue of A$9.6B in FY2025 versus A$8.8B in FY2021, a compound +2.5%/yr. Reported net income was A$514M in FY2025, compounding −20.9%/yr from FY2021.
Is SHL fairly valued? → Check now
Recent news
- CellCarta and Sonic Healthcare Establish Strategic Partnership to Commercialize Companion Diagnostics Through Lab Network
- Australia pledges A$1.8 billion for Medicare clinics amid widening deficit fears
- Sonic Healthcare (ASX:SHL) earnings and shareholder returns have been trending downwards for the last five years, but the stock lifts 7.4% t
- Painful week for individual investors invested in Sonic Healthcare Limited (ASX:SHL) after 4.2% drop, institutions also suffered losses
External third-party headlines (Yahoo Finance, Reuters and others) — not an editorial selection, not financial advice.
Similar stocks
6 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate (as of Jun 25, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Thermo Fisher Scientific Inc TMO | $482.04 | $202.02 | -58% |
| Danaher Corporation DHR | $183.63 | $87.65 | -52% |
| 2359 2359 | HK$152.80 | HK$120.99 | -21% |
| WuXi AppTec Co WUXAY | $18.59 | $25.09 | +35% |
| IDEXX Laboratories, Inc IDXX | $545.73 | $255.77 | -53% |
| Lonza Group LZAGY | $63.74 | $25.98 | -59% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is SHL (SHL) undervalued?
What is the fair value of SHL?
What is the quality score of SHL?
What is the revenue of SHL (SHL)?
What is the net profit margin of SHL?
Does SHL pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.